Key result
Prior treatment with chemotherapy in breast cancer survivors was associated with a non-significant increase in the odds of congestive heart failure (OR 1.43).
Why the study?
Cardiovascular disease accounts for 35% of non-cancer deaths in breast cancer survivors aged > 50 years, driven by cardiotoxic cancer therapies and overlapping risk factors, warranting examination of cardiovascular disease frequency.
Cross-Sectional (n=164)
Yes
Odds Ratio: 1.43 (95% CI 0.57–361.67)
p-value: p=0.1059
Breast cancer survivors exhibit a high prevalence of cardiovascular risk factors, underscoring the need for appropriate cardiovascular risk management to prevent morbidity and mortality in this population.
May support CVD surveillance in breast cancer survivors >50; leaves open optimal risk stratification in larger cohorts.
BACKGROUND: Among breast cancer survivors age > 50 years, deaths due to cardiovascular disease account for 35% of non-cancer related deaths. The increases in cardiovascular disease among breast cancer survivors is due to the cardiotoxic effects of breast cancer treatment and to overlapping risk factors for breast cancer and cardiovascular disease. METHODS: We conducted a study of a sample of 164 breast cancer patients in order to examine the frequency of cardiovascular disease. The overall objective was to examine the frequency of high blood pressure, myocardial infarction, cardiomyopathy, congestive heart failure, stroke, and venous thrombosis/thromboembolism among women who have been diagnosed with stage I-IV breast cancer and who had completed primary therapy for the disease. Data were collected by postal survey and abstraction of electronic medical records. RESULTS: A high percentage of the women (62.8%) had a reported history of high blood pressure. Fifty percent of the women had a reported history of high cholesterol. About 8.3% of the women were current smokers and 36.0% were former smokers. About 23.8% of the women had a reported history of diabetes. About 4.9% of the women had a reported history of congestive heart failure and 6.1% had a history of stroke. DISCUSSION: Additional studies are needed of cardiovascular risk factors and adverse cardiovascular events among breast cancer survivors. Of particular concern is whether patients with hypertension, hypercholesterolemia, and diabetes are receiving appropriate therapy to reduce their cardiovascular risk and prevent morbidity and mortality from adverse cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Coughlin et al. (2020) conducted a cross-sectional in Breast cancer survivors (n=164). Chemotherapy vs. No chemotherapy was evaluated on History of congestive heart failure (OR 1.43, 95% CI 0.57-361.67, p=0.1059). Prior treatment with chemotherapy in breast cancer survivors was associated with a non-significant increase in the odds of congestive heart failure (OR 1.43).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: